Safety and Efficacy of Combination SARS-CoV-2 Neutralizing Monoclonal Antibodies Amubarvimab Plus Romlusevimab in Nonhospitalized Patients With COVID-19
Teresa H. Evering(Cornell University), Lara Hosey, Rachel Bender Ignacio, Mauricio Pinilla(University of North Carolina at Chapel Hill), Joseph J. Eron(University of North Carolina at Chapel Hill), Carlee Moser(Harvard University), Arzhang Cyrus Javan(National Institutes of Health), Davey M. Smith(University of San Diego), Ji Ma(China Agricultural University), Bharat Mocherla(Brigham and Women's Hospital), Eric S. Daar(UCLA Medical Center), Mark J Giganti(Harvard University), Judith S. Currier(University of California, Los Angeles), Qing Zhu(Altimmune (United States)), Yan Li(Union Hospital), Lijie Zhong(Gilead Sciences (United States)), David M. Margolis(University of North Carolina at Chapel Hill), Michael D. Hughes(Virginia Tech), Rinki Deo(Brigham and Women's Hospital)
Cited by 31
Related Papers
Prevention of HIV-1 Infection with Early Antiretroviral Therapy
|New England Journal of Medicine|2011|7k
Antiretroviral Treatment of Adult HIV Infection
|JAMA|2012|2.5k
Treatment with Indinavir, Zidovudine, and Lamivudine in Adults with Human Immunodeficiency Virus Infection and Prior Antiretroviral Therapy
|New England Journal of Medicine|1997|1.9k
Antiretroviral Therapy for the Prevention of HIV-1 Transmission
|New England Journal of Medicine|2016|1.7k